Kornimate/medical-research-clean huggingface dataset:
establishment of a database of patients suffering from obesity with a medical treatment

Conditions: BMI Greater Than 30

Summary: obesity is a public health problem, given its prevalence (15% in france in 2012, obépi survey) but also by the complications that it generates. we were firstly, intersted in bone mineral density during obesity. we were able to confirm in an observational study that bmd (z-score)was augmented. we also showed, for the first time, that this increase in z-score was dependent on sex, severity of obesity and age but also bone site. if the increase in bmd at the level of the bearing zones seems logically to be explained by the hypothesis that the mechanical stresses have an osteogenic effect on the bone tissue, the latter can not in any way respond to the concomitant increase in bmd at non-bearing areas such as the radius.these results suggest that changes in certain systemic compounds induced by obesity may interfere with bone metabolism. recent data also suggest a change in the concentration of pro-glucagon peptides (glp-1, glicentin, glucagon, etc.) in obese subjects and in bariatric surgery). although body composition and its variation after surgery could be largely involved in the modification of these peptides, no data on these potential relationships is currently available. however, no data are available for baseline body composition and weight loss data. finally, 80% of obesity is associated with insulin resistance, a key mechanism in the pathophysiology of type 2 diabetes. a metabolically healthy obesity phenotype is described, although the definition criteria are not consensual.the evolution of this phenotype with aging and with the duration of evolution of obesity is not well described. our goal is to create a database of weight-bearing patients in the care setting and to determine the "hormonal dialogue" between peripheral (muscular and adipose) and bone tissues, which may be associated with changes in body composition during obesity and aging, and that according to sex.


Eligibility criteria:
inclusion criteria: - obese patients age above 18 years old exclusion criteria: - non agreement of inclusion

Keywords: obesity nutrition disorders
interventional program educates, identifies + overcomes barriers to complete screening mammography

Conditions: Breast Cancer

Summary: the purpose of this study is to identify interventions that are designed to better serve women who are homeless, with a speciﬁc focus on increasing screening rates and decreasing late stage breast cancer diagnosis among this high-risk understudied community of women. as a result, the study team hopes to influence the broader homeless healthcare initiative

the goal of this program will be to bring 6-8 mobile on site mammography clinics to homeless shelters that house women over a two-year period. prior to arrival, clinic staff will recruit women to participate in a survey to elucidate beliefs and barriers around breast health and mammography. after the survey, clinic staff will conduct the outreach program, consisting of a brief educational session about breast health and mammography for any participating women. education will be tailored to be culturally appropriate, and delivered by a female public health educator with experience in the underserved community. the educational session will explain screening options and address common barriers. after education, eligible women who wish to receive a mammogram may receive one from the on-site mobile mammography clinic free of charge. throughout the day, the community educator will also lead activities and meals will be provided in order to create a festive atmosphere and inspire a sense of community among the women. spanish speaking staff will be available for the educational sessions.

Eligibility criteria:
inclusion criteria: * women under age 40 who present with high risk breast cancer related symptoms or a first degree relative with breast cancer * have not had mammogram in the last 12 months * resident at a homeless shelter or transitioning housing facility. exclusion criteria: - participant experiencing homelessness under age 40 who do not present with high risk breast cancer related symptoms or a first degree relative with breast cancer.
weight management intervention in college: a pilot rct

Conditions: Obesity and Overweight

Summary: this pilot randomized controlled trial will examine a behavioral weight loss intervention that uses a "small change" approach fro emerging adult college students with overweight/obesity. the primary aim is to assess student acceptability and clinically-meaningful weight changes.

forty percent of emerging adults (age 18-25) have overweight or obesity, which is unlikely to remit and has significant health consequences. however, emerging adults are underrepresented in traditional weight loss programs, drop-out at high rates, and have blunted weight loss outcomes. one potential way to improve participation is to offer bwlis in college health service centers to reduce barriers to participation. approximately 40% of emerging adults are enrolled in a postsecondary institution and college health centers are used widely by students. moreover, delivering an intervention with design features that are responsive to emerging adult preferences and lifestyles may also improve intervention effectiveness and attractiveness. the "small change" (sc) approach to weight loss addresses emerging adult barriers to engagement by focusing on reducing calories through a few self-selected, specific changes to current obesogenic behaviors, requiring less time and effort than traditional behavioral weight loss interventions (bwli) and promoting autonomy and self-efficacy. the sc approach has been used effectively for weight loss in other populations. this randomized controlled pilot study is part of a larger study that aims to develop and refine a novel and effective bwli based on a sc approach that is designed for emerging adults and for implementation in college health centers, an accessible care setting. the primary aim of this substudy is to assess acceptability and feasibility of the intervention and to get a preliminary understanding of potential clinical benefit for participants.

Eligibility criteria:
inclusion criteria: * bmi of 25 or greater * enrolled at college/university where study will take place * english-speaking exclusion criteria: * history or current diagnosis of anorexia nervosa, bulimia nervosa, or alcohol use disorder (current symptoms also assessed at screening using validated screening questionnaires) * participation in another formal weight loss program or current utilization of obesity medications * current or recent pregnancy * psychiatric hospitalization in the past 12 months * recent weight loss of 5% body weight or more * history of bariatric surgery * severe food or physical activity restrictions that would interfere with treatment recommendations

Keywords: obesity college students behavioral weight loss intervention small changes
study comparing optimized 5-fu dosing and standard dosing in metastatic colorectal cancer patients treated with mfolfox6

Conditions: Colorectal Cancer, Metastatic

Summary: the purpose of this study is to compare ondose® based pharmacokinetic administration of 5-fu versus standard body surface area (bsa) based administration of 5-fu in patients with metastatic colorectal cancer treated with mfolfox6, with or without bevacizumab, to determine if the use of ondose® achieves an improvement in the overall response rate (orr) relative to bsa dosing response.


Eligibility criteria:
selection criteria: * patients with histologically confirmed metastatic colorectal cancer * no prior chemotherapy for the treatment of metastatic colorectal cancer * at least one measurable lesion by ct or mri of ≥ 20 mm (if conventional ct scan) or ≥ 10 mm (if spiral ct scan) * ecog performance status (ecog-ps) status ≤ 2 * at least 18 years of age * life expectancy \> 6 months * must be able and willing to give written informed consent * women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use acceptable contraceptive methods (abstinence, intrauterine device \[iud\], oral contraceptive or double barrier device), and must have a negative serum or urine pregnancy test within 1 week prior to beginning treatment on this trial. nursing patients are excluded. sexually active men must also use acceptable contraceptive methods (abstinence, condom). * anc count greater than or equal to 1,500/ mm³ * platelets greater than or equal to 100,000/ mm³ * serum creatinine less than or equal to 2x upper limit of normal (normal range (male): 97-137 ml/min; (female): 88-128 ml/min) * alanine aminotransferase (alt) and aspartate aminotransferase (ast) less than or equal to 3x the upper limit of normal (≤ 5.0 x uln is acceptable if liver has tumor involvement) (alt normal range: \< 41 iu/l (male), \< 31 iu/l (female); ast normal range: \< 37 iu/l (male), \< 31 iu/l (female)). * prothrombin time (pt), activated partial thromboplastin time (aptt) and inr ≤ 1.5 x uln (inr normal range: 0.8-1.2) or in the therapeutic range if on anticoagulation. * hemoglobin greater than or equal to 9 gm/dl (may be corrected by transfusion prior to 5-fu treatment with investigator approval).

Keywords: colorectal cancer, metastatic folfox6 5-fu first line bevacizumab
familien-scout: comprehensive support for families with a parent suffering from cancer

Conditions: Families With Minor Children and One Parent Suffering From Cancer

Summary: when a parent with minor children falls ill with cancer, it is extremely stressful for all of the family members, including the partner and children. familiar everyday routines are often disrupted even at an early stage, and for a prolonged period. financial difficulties, the threat represented by the uncertain course of the disease, and worries about the children's future have a cumulative effect. the affected families are thereby pushed to their limits organizationally and emotionally. the burden involved tends to be underestimated, and secondary psychological conditions often develop among all the family members. they often do not have adequate access to support. the aim of this project is to establish a care management system that provides support for families with underage children in which one parent is seriously ill. in order to reduce the burden on families, "family scouts" are to be used who can provide advice and information at an early stage. they are intended to encourage families to discuss things openly, and they should also facilitate access to all the support services available. the project will evaluate whether the use of family scouts reduces the burden on the family in comparison with families who do not have a family scout. for this purpose, investigations will be carried out before and after the family scouts are deployed. standardized questionnaires, interviews, and routine data from the participating health-insurance companies will provide the basic data.


Eligibility criteria:
inclusion criteria: * confirmed icd diagnosis of cancer in one parent * custody of at least one underage child * adequate knowledge of german * availability of informed consent to participate in the study from the patient and/or healthy parent and linkage to questionnaire data and routine data exclusion criteria: * withdrawal of consent by the ill or healthy parent * relevant cognitive limitation, advanced dementia * individuals who are in relationships of dependence or employment to the project managers or their representatives
examination of the effects of liraglutide on the mode of action of insulin detemir

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in the united states. the aim of this clinical trial is to investigate whether chronic liraglutide administration affects the mode of action (pharmacokinetics) of insulin detemir


Eligibility criteria:
inclusion criteria: * diagnosed with type 2 diabetes * bmi less than 45.0 kg/m2 * insulin naive * currently treated with oral anti-diabetic drugs (oads) and metformin with a hba1c between 7.0 and 9.5% or currently treated with metformin only with a hba1c between 7.0 and 10.0% exclusion criteria: * any clinically significant disease other than type 2 diabetes * currently using daily insulin * thiazolidinione use or other injectable diabetes medications within the last 3 months
intensive chemotherapy and autotransplantation for patients with newly diagnosed anaplastic oligodendroglioma

Conditions: CNS Cancer; CNS BRAIN

Summary: the purpose of this study is to see how effective treatment of high doses of chemotherapy is for your tumor. we will also be looking at the side effects and risks of this treatment. you will receive very high doses of chemotherapy. high doses of chemotherapy can destroy tumor cells, but it can also destroy normal bone marrow cells. these cells produce white blood cells (which fight infection), red blood cells (which carry oxygen) and platelets (which allow your blood to clot). with too few of these cells there is a serious risk of infection and bleeding. therefore, before treatment begins, we will collect some of your own blood cells, called peripheral blood progenitor cells (pbpcs). these cells help create new blood cells. the pbpcs are frozen and saved while you are being treated. then at the end of treatment, your pbpcs are thawed and given back to you. these healthy pbpcs will replace the blood cells that the high dose chemotherapy destroys and allow your bone marrow to recover and produce blood cells. in a prior study we treated 69 patients in a similar way. more than half were able to avoid or delay brain radiation. this new study will use a different high dose chemotherapy regimen.


Eligibility criteria:
inclusion criteria: * pathologic evidence of an anaplastic oligodendroglioma. for this study, world health organization classification criteria will be used. central pathology review must take place prior to high-dose therapy but need not occur prior to study entry and induction therapy. * pathologic evidence of an anaplastic mixed glioma (i.e. oligoastrocytoma). again, histopathologic diagnosis will be made using world health organization classification criteria. to qualify as a mixed tumor there must be a minimum of 25% oligodendroglial element. central pathology review must take place prior to high-dose therapy but need not occur in advance of enrollment or induction therapy. * the diagnostic surgical procedure may have been a complete resection, partial resection, or biopsy. * karnofsky performance status \> or equal to 60. * granulocyte count \> or equal to 1.5 x 109/l. * platelet count \> or equal to 100 x 109/l * sgot \< than or equal to 2x upper limit of normal. * serum creatinine \< than or equal to 1.5x upper limit of normal * bilirubin \< than or equal to 1.5x upper limit of normal * all patients must sign written informed consent. exclusion criteria: * systemic or leptomeningeal metastases (excluding contiguous leptomeninges) * prior cranial radiotherapy or systemic chemotherapy * other concurrent malignancy (with the exception of cervical carcinoma in situ or basal cell carcinoma of the skin) or serious illness if this would interfere with the prescribed treatment. * pregnant or lactating women * refusal to use effective contraception

Keywords: brain cns temozolomide busulfan thiotepa
fostrspace-casa r61/r33

Conditions: Substance Use

Summary: the purpose of this study is to understand how an online digital health application (app) called fostrspace can reduce substance use among youth (ages 13-20 years old) in foster care.

the goal of this clinical trial is to identify gaps in substance use prevention across existing casa trainings and the fostrspace app for foster youth and test how substance use trainings for casa volunteers could help facilitate fostrsace app referrals to reduce and prevent substance use among casa youth.

Eligibility criteria:
inclusion criteria: * adolescents and young adults will be eligible if they are age 13-20, are proficient in english, have an assigned casa worker, and have a device with web access. * casas (ages 18 and over) will be eligible if they are assigned to a youth between the ages of 13- 20. exclusion criteria: * youth: exclusion criteria include being non-english speaking, being within 3 months of ending with casa services, cognitive impairment that precludes ability to provide informed consent. * casa: exclusion criteria include being non-english speaking and working with a youth who is within 3 months of ending with casa services.

Keywords: foster youth substance use mhealth
to investigate the effect of early community-care program on fracture hip patient

Conditions: Fracture

Summary: the early community-care program is well-known rehabiliation for the fracture hip patient. for the discharged fracture hip patient from hospital, it is worth to investigate the effect of early mobilization program to improve their physical and psychological aspects.

60 fractured hip patient will randomized allocated into intervention group and control group. the community-care include nursing care, physiotherapy and home modification according to the condition of the patient. the intervention will received community-care program for 12 weeks. two sessions per week and total 24 sessions. the control group will receive the traditional medication. the outcome measure include elderly mobility scale and happiness scale. the measurement will take at initial and completion of the program. spss will be used for data analysis.

Eligibility criteria:
inclusion criteria: * fracture hip patients discharged from queen mary hospital exclusion criteria: * cognitive impairment

Keywords: physical psychological fracture hip
acupuncture therapy on dysphagia in parkinson's disease

Conditions: Parkinson Disease

Summary: from june 2019 to may 2021, we conducted a randomized controlled study, including dysphagic patients with parkinson's diseases who were admitted to the department of rehabilitation medicine in 3 hospitals in china. the participants were divided randomly into the experimental group and the control group, with 56 in each one. both two groups were given routine treatment and swallowing rehabilitation training. moreover, the experimental group was given acupuncture therapy.

from june 2019 to may 2021, we conducted a randomized controlled study, including dysphagic patients with parkinson's diseases who were admitted to the department of rehabilitation medicine in 3 hospitals in china. the participants were divided randomly into the experimental group and the control group, with 56 in each one. both two groups were given routine treatment and swallowing rehabilitation training. moreover, the experimental group was given acupuncture therapy. the study lasted 42 days (6 weeks) for each participant. specifically, our main focus is on the study of lianquan, shanglianquan (depression between the hyoid bone and the lower border of the mandible), yifeng, fengchi, wangu, fengfu, yamen, neidaying (depression of 1 inch below the anterior margin of the mandible), jinjin, yuye, posterior pharyngeal wall (both sides of the uvula).

Eligibility criteria:
inclusion criteria: * age \>18 years. * meeting the diagnostic criteria for parkinson's disease developed by the neurology branch of the chinese medical association in 2006. * diagnosed with dysphagia confirmed by the video fluoroscopic swallowing study. * water swallow test\> level 3. * stable vital signs, conscious, able to cooperate with assessment and treatment. exclusion criteria: * dysphagia possibly caused by other reasons, such as cerebrovascular disease, trauma, neuromuscular diseases, malignant diseases of the pharynx and larynx, and digestive tract diseases. * history of mental diseases or use of antipsychotics. * complicated with cognitive impairment or consciousness dysfunction. * simultaneously suffering from severe liver, kidney failure, tumors, or hematological diseases.
phase ⅰa clinical study of hawthorn red pigment combined with standard analgesic for refractory cancer pain

Conditions: Hawthorn Red Combined Refractory Cancer Pain

Summary: to evaluate the safety and tolerance of hawthorn red pigment in the treatment of cancer pain determine the maximum tolerated dose (mtd, if any) of hawthorn red pigment and the recommended dose for phase ii clinical study (rp2d)


Eligibility criteria:
inclusion criteria: 1. patients aged 18-80 years with malignant tumor confirmed by pathology; 2. refractory cancer pain, that is, patients coexist: 1) digital score of persistent pain ≥ 4 points and / or number of eruptive pain ≥ 3 times / day; 2) following the relevant guidelines for cancer pain treatment, the pain relief of patients treated with opioids alone and / or combined with adjuvant analgesics for 1-2 weeks is still unsatisfactory and / or intolerable adverse reactions occur; 3. patients who need chemotherapy, long-term hormone, targeted therapy or bisphosphate therapy had stable anti-tumor therapy before randomization; 4. patients or their nursing staff can fill in the survey form; 5. correctly understand and cooperate with medical staff in medication guidance; 6. no mental illness; 7. ecog-ps ≤ 3 points; 8) did not participate in the drug test (including the test drug) within one month before the test; 8. the subjects volunteered and signed the informed consent. exclusion criteria: 1. patient is diagnosed with non cancerous pain or pain of unknown cause; 2. postoperative pain of patients; 3. patients with paralytic intestinal obstruction; 4. patients with metastatic brain cancer; 5. patients with opioid allergy / addiction; 6. abnormal laboratory results with obvious clinical significance, such as creatinine ≥ upper limit of normal value, alt or ast ≥ 2.5 times of upper limit of normal value (liver metastasis patients or primary liver cancer ≥ 5 times of upper limit of normal value), or child c level of liver function; 7. patients who cannot take drugs orally; 8. uncontrollable nausea and vomiting; 9. patients with a history of gastritis and gastric ulcer; 10. patients who need to use nonsteroidal drugs and steroid hormone drugs for analgesia; 11. diabetes patients who can't control blood sugar stably; 12. pregnant and lactating women; subjects with pregnancy plans within 1 month after the trial (including male subjects); 13. alcoholics; 14. patients with cognitive impairment; 15. patients with severe depression; 16. diseases and conditions that other researchers consider not to be included.
coordinated assessment of notifications of trials containing overt published errors

Conditions: Heart Failure

Summary: clinical research, like all science, is self-correcting, with errors detected by the scientific community and communicated to the publishing journals, which then relay the information (and its resolution) to its readers. if this relaying process fails, science grinds to a halt. in this study we are testing its integrity.

this prospective study documents the outcome of notification to journal editorial boards (or equivalent authorities) of factually incorrect or inconsistent claims, in reports they have published.

Eligibility criteria:
inclusion criteria: * report of a clinical trial in humans of treatment of heart disease with bone marrow derived stem cells * report containing discrepancy by reference to same report or another report exclusion criteria: * discrepancy has already been corrected by an erratum

Keywords: discrepancy committee on publication ethics correction erratum retraction